Do you want to read an article? Please log in or register.
Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial
COPD
RECOMMENDED
Related content
COPD
Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial
Respir Res.
Maltais F, Naya IP, Vogelmeier CF, Boucot IH, Jones PW, Bjermer L, Tombs L, Compton C, Lipson DA, Kerwin EM
doi: 10.1186/s12931-020-01451-8.
RECOMMENDED
COPD
Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ther Adv Respir Dis
Vogelmeier CF, Kerwin EM, Bjermer LH, Tombs L, Jones PW, Boucot IH, Naya IP, Lipson DA, Compton C, Barnes N, Maltais F
doi: 10.1177/1753466620968500
Further Publications
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of the IMPACT Trial
Chest.
Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA
doi: 10.1016/j.chest.2020.09.253.
RECOMMENDED
COPD
Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Res.
Maltais F, Bjermer L, Kerwin EM, Jones PW, Watkins ML, Tombs L, Naya IP, Boucot IH, Lipson DA, Compton C, Vahdati-Bolouri M, Vogelmeier CF
doi: 10.1186/s12931-019-1193-9.
RECOMMENDED
Asthma
Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Res
Lemiere C, Taillé C, Lee JK, Smith SG, Mallett S, Albers FC, Bradford ES, Yancey SW, Liu MC
doi: 10.1186/s12931-021-01767-z
RECOMMENDED
COPD
Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
Adv Ther.
Naya IP, Tombs L, Lipson DA, Compton C
doi: 10.1007/s12325-018-0771-4.
COPD
Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study
Respir Res.
Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA
doi: 10.1186/s12931-018-0724-0.
COPD
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Int J Chron Obstruct Pulmon Dis.
Beeh KM, Beier J, Candler H, Wittig T
doi: 10.2147/COPD.S11765
Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms; post-hoc analyses of three randomized controlled trials
J Asthma
Kerwin E, Barnes N, Gibbs M, Leather D, Forth R, Jacques L, Yates LJ
doi: 10.1080/02770903.